Regulatory reflections concerning the state of biotechnology progress

Drug Information Journal

Volumn 30, Issue 1, 1996, Pages 41-46

  Fisher, Melvin P ^a   Pascucci, Virginia L ^a  

^a Department of Regulatory Sciences ^*  (United States)

Author keywords

Approvals; Biotechnology; Development process; Resources

Indexed keywords

ADAGON; ADENOSINE DEAMINASE; ALGLUCERASE; ALPHAN3 INTERFERON; ALTEPLASE; ASPARAGINASE; ASPARAGINASE MACROGOL; DORNASE ALFA; HEPATITIS B VACCINE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY B.72.3; OKT 3; ONCOSCINT CR OV; PEGADEMASE; PROTOPINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; SOMATREM; TYPHOID VACCINE; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; PRIORITY JOURNAL; REVIEW;

EID: 0030052295     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000106     Document Type: Review

References (1)

1. Bienz-Tadmor B, Brown JS. Biopharmaceuticals and Conventional Drugs: Comparing Development Times. BioPharm. 1994;44-49.